viewReNeuron Group PLC

ReNeuron CFO 'very encouraged' with stroke study results

ReNeuron Group Plc (LON:RENE) has delivered encouraging results from its phase II clinical study treating stroke patients with its CTX stem cell candidate.

CFO Michael Hunt tells Proactive: ''We're very encouraged by these results. The objective of the study  was to see if we could garner a strong enough clinical signal in disabled stroke patients to warrant taking this drug into much larger, pivotal clinical development''.

''I'm pleased to say that the readouts we've had from the study so far have met that objective''.

Quick facts: ReNeuron Group PLC

Price: 128.6 GBX

Market: LSE
Market Cap: £40.94 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...



ReNeuron seeing increased interest across its assets from potential licensee...

ReNeuron Group PLC (LON: RENE) CFO Michael Hunt sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco. The UK-based developer of cell-based therapeutics in is the U.S. engaging with U.S. investors, and is looking to build out its business development...

on 01/11/2019

2 min read